TKT and neoplasm: As shown in Figure 4D, the treatment reduced the tumor burden by an average of 9.5-fold (p < 0.01) in comparison with the pSLAM-HSV1-tk-mCherry-gRNA only controls or of 7.3-fold (p<0.01) with Cas9D10A-EGFP only controls.